Drug Profile
Research programme: antibacterials - Fulcrum Pharmaceuticals
Alternative Names: Adaptive ligands - Fulcrum; Anti-MRSA BAR agents - Fulcrum; Anti-Pseudomonas BAR agents - Fulcrum; FL 233Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Fulcrum Pharmaceuticals
- Class Small molecules
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections; Methicillin-resistant Staphylococcus aureus infections; Pseudomonal infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pseudomonal-infections in USA